Experimental drug BVD-523 tested for rare eye cancer, but trial stopped early

NCT ID NCT03417739

Terminated Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 28, 2026 · Updated 2 times

Summary

This study tested a drug called BVD-523 (Ulixertinib) in 13 people with advanced uveal melanoma, a rare eye cancer that has spread. The drug works by blocking certain proteins that help cancer grow. The trial was terminated early, so results are limited and it's unclear how well the drug works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BVD-523 (Ulixertinib), a targeted therapy that blocks certain proteins (ERK1 and ERK2) to slow cancer growth
What this could lead to: If successful, this could point toward a new treatment option for people with advanced uveal melanoma, a rare eye cancer that has spread.
What could go wrong: This was a small, early-phase trial that was terminated, meaning it may not have shown enough benefit or had other issues. Results are limited and may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UVEAL MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

uveal melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UVEAL MELANOMA

Contacts and locations

Locations

Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Massachusetts General Hospital

Boston, Massachusetts, 02214, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.